Propeller Health said today that it landed a collaborative agreement with Novartis (NYSE:NVS) to develop a custom add-on sensor for the Breezhaler inhaler. The partnership is focused on patients with chronic obstructive pulmonary disease in Europe. The Breezhaler is a capsule-based, dry powder inhaler and is a part of Novartis’ portfolio of COPD therapies. The custom […]
Wall Street Beat
Allergan ticks up on Q4, 2016 beats
Allergan (NYSE: AGN) shares ticked up today after the company reported 4th-quarter and full-year earnings – and a 2017 sales forecast – that beat expectations on Wall Street. The drugmaker narrowed its losses by 90% to -$70.2 million, or -20¢ per share, on sales growth of 7.1% to $3.86 billion for the 3 months ended Dec. 31, […]
Aura Biosciences wins FDA nod for light-activated ocular melanoma treatment
Aura Biosciences said today that the FDA approved its Investigational New Drug Application for the company’s light-activated viral nanoparticle conjugates for the treatment of ocular melanoma. The federal watchdog’s approval allows Cambridge, Mass.-based Aura to move forward with initial clinical tests of AU-011. The Phase Ib open-label clinical trial, which is currently enrolling, is designed to […]
FDA accepts Intarcia’s NDA for diabetes drug-device combo
Intarcia Therapeutics said today that the FDA accepted its New Drug Application for the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The Medici drug-device combo delivers exenatide subcutaneously using a match-sized osmotic pump placed under the skin in an in-office procedure. The subcutaneous delivery system uses technology to stabilize proteins, peptides, antibody fragments […]
Pulmatrix raises $3m in direct offering
Pulmatrix (NSDQ:PULM) said today that unnamed institutional investors agreed to purchase approximately $3.3 million of shares of common stock in a direct offering. The company said it plans to sell 950,000 shares at $3.50 apiece. Pulmatrix expects the offering, which will close next week, to bring in $3.0 million in proceeds to use for general […]
Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes
Shares in Amgen (NSDQ:AMGN) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for its cholesterol drug, Repatha. The Thousand Oaks, Calif.-based company posted profits of $1.94 billion, or $2.59 per share, on sales of $5.97 billion for the 3 months ended Dec. 31, for bottom-line […]
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said […]
Braeburn pulls the plug on $150m IPO, citing market conditions
Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions. The Princeton, N.J.-based company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by offering 7,692,308 shares of its common stock at $18.00 to $21.00 apiece. The company […]
Nordisk tumbles on lowered outlook
Shares in Novo Nordisk (NYSE:NVO) fell -9% this morning after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results and lowered its outlook for 2017. The Danish company posted profits of 8.7 billion Danish kroner, or $1.26 billion USD, on sales of 29.57 billion kroner for the 3 months ended Dec. 31, for bottom-line growth of […]
Advanced Inhalation Therapies raises $10m
Advanced Inhalation Therapies closed a $10.2 million offering yesterday. According to regulatory filings, 39 investors contributed to the offering, which made its 1st sale on Jan. 13. The Israel-based company is developing a drug delivery device to treat severe respiratory infections and lung diseases using a high dose of nitric oxide. The company plans to use $604,000 […]
